In an article on a federal probe into Johnson & Johnson’s marketing of an antipsychotic drug, the Wall Street Journal quoted Dean  on the risks the company might face in going to trial.

In filings with the Securities and Exchange Commission, J&J acknowledged a federal investigation into the firm’s marketing of Risperdal for unapproved uses, the article said, citing sources that set the potential settlement at $1 billion.

Should the New Jersey-based company not agree to the terms of the settlement sought by the federal government, the resulting trial, if unsuccessful for J&J, could result in more costly civil and criminal legal actions brought by patients and states, Dennis said.

The article appeared in the May 13, 2011 edition of the newspaper.